Bottom Fish Stocks (between .10 and$10)

[zenvesting]

Biophan news after close:

Biophan Announces Development of Breakthrough Long-Life Biothermal Battery
Friday May 14, 4:01 pm ET
Company Acquires Majority Interest in Biothermal Battery Nanotechnology Venture Targeting Approximately $500 Million Global Market


ROCHESTER, N.Y.--(BUSINESS WIRE)--May 14, 2004-- Biophan Technologies, Inc. (OTCBB: BIPH - News), a leading developer of next generation biomedical technology, announced today that it has acquired a majority interest in TE-Bio, LLC, a company developing a breakthrough, long-life power source for use in implanted medical devices, such as pacemakers, defibrillators, neurostimulators, and drug pumps.
ADVERTISEMENT


The technology is based on a patented innovation in the utilization of thermoelectric materials, using nanoscale-based, thin-film materials to convert thermal energy produced naturally by the human body into electrical energy. The resulting power can be used to "trickle charge" batteries for medium-power devices such as defibrillators, or directly power low-energy devices like pacemakers. The Company will be displaying the technology to over 6,000 healthcare professionals at the NASPE--Heart Rhythm Society's Heart Rhythm 2004 Conference, May 19-22, 2004 in San Francisco, CA.

TE-Bio is developing an implantable power system that has the potential to provide as much as a 30-year life--a five-fold increase in service life compared to existing technology. The technology is anticipated to dramatically extend the service life of neurostimulators and drug pumps that are used for treatment of tremors, diabetes, and chronic pain. Furthermore, since these devices can be implanted in young patients, the combination of TE-Bio technology and extended device life may reduce the number of replacement implants needed throughout a patient's life. For further information or to view the patent, please visit www.biophan.com/biothermal.php.

The use of implantable electronic medical devices is increasing worldwide due, in part, to the aging of the population and the increased use of these devices for both diagnostic and therapeutic treatments. However, existing systems share a major shortcoming - the need for a reliable electrical power source that does not require periodic surgical removal and replacement. Virtually all medical devices require replacement. It is estimated that neurostimulators, used to treat Parkinson's disease, last an average of three years; defibrillators last about five to six years, and pacemakers an average of about eight years.

Thermoelectric materials are special types of semiconductors that produce electricity when one side of the material is heated and the other is cooled. These materials have been used to generate electricity on spacecraft, such as the Voyager space probe, that are too far away from the sun for solar cells to operate. However, the low energy efficiency of existing materials has required very large temperature differences to produce a sufficient amount of usable power.

Recent advances in nanotechnology have now made new thermoelectric materials with the potential for generating sufficient electrical power for implantable medical devices, in part due to the ability to produce many more semiconductors on a surface.

TE-Bio holds a worldwide exclusive license to patent #6,640,137 "Biothermal Power Source for Implantable Devices" from Biomed Solutions, LLC.

"The realization of generating enough energy to power a pacemaker, or extend the life of a defibrillator, from the heat differential in our bodies, has been brought within striking distance by the remarkable revolution in materials science and advances in nanotechnology," stated Michael Weiner, CEO of Biophan.

Conference Call and Webcast

The Company will discuss the impact and market opportunity represented by this breakthrough technology on a conference call and webcast on Tuesday, May 18 at 12:00 pm Eastern. Following the discussion, Michael Weiner, president of Biophan, and other members of the executive management team will be available to answer questions regarding the technology and other technology which the Company is currently developing. Participants may ask questions during the Q & A segment of the call or, if they prefer, may e-mail questions in advance of the call to Randy Lewis, senior vice president of Trilogy Capital Partners, [e-mail]. To access the call, Investors should call at [phone], code 731878 or from an international location by calling [phone].